Clinical Trials Browser

Terminated × NIH × Triple Negative Breast Neoplasms × Clear all

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02474173 2022-11-04

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1 Terminated

1 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Terminated

12 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01151449 2017-04-11

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01238133 2015-09-04

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01071564 2015-04-15

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms